IlluminaILMN
About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Employees: 9,300
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5% less repeat investments, than reductions
Existing positions increased: 263 | Existing positions reduced: 277
2% less funds holding
Funds holding: 771 [Q1] → 754 (-17) [Q2]
3.67% less ownership
Funds ownership: 91.83% [Q1] → 88.16% (-3.67%) [Q2]
14% less first-time investments, than exits
New positions opened: 106 | Existing positions closed: 123
18% less funds holding in top 10
Funds holding in top 10: 11 [Q1] → 9 (-2) [Q2]
27% less capital invested
Capital invested by funds: $20B [Q1] → $14.7B (-$5.3B) [Q2]
30% less call options, than puts
Call options by funds: $171M | Put options by funds: $243M
Research analyst outlook
15 Wall Street Analysts provided 1 year price targets over the past 3 months
15 analyst ratings
Argus Research Jasper Hellweg 67% 1-year accuracy 4 / 6 met price target | 7%upside $150 | Buy Upgraded | 28 Aug 2024 |
Daiwa Capital Narumi Nakagiri 67% 1-year accuracy 2 / 3 met price target | 10%upside $154 | Buy Upgraded | 16 Aug 2024 |
Scotiabank Sung Ji Nam 67% 1-year accuracy 10 / 15 met price target | 17%upside $164 | Sector Outperform Maintained | 15 Aug 2024 |
TD Cowen Dan Brennan 63% 1-year accuracy 19 / 30 met price target | 3%upside $144 | Buy Upgraded | 14 Aug 2024 |
RBC Capital Conor McNamara 59% 1-year accuracy 23 / 39 met price target | 73%upside $242 | Outperform Reiterated | 14 Aug 2024 |
Financial journalist opinion
Based on 10 articles about ILMN published over the past 30 days